Search Results - Yasuto Kinose
- Showing 1 - 9 results of 9
-
1
-
2
Clinical trial assessing the safety of edoxaban with concomitant chemotherapy in patients with gynecological cancer-associated thrombosis (EGCAT study) by Tadashi Oride, Kenjiro Sawada, Aasa Shimizu, Yasuto Kinose, Tsuyoshi Takiuchi, Michiko Kodama, Kae Hashimoto, Eiji Kobayashi, Eiji Nakatani, Tadashi Kimura
Published in Thrombosis Journal (2023-05-01)Get full text
Article -
3
Laparoscopic surgery for left ovarian hemorrhage in a patient with an implantable left ventricular assist device on antithrombotic therapy and a history of right salpingo-oophorect... by Yasuto Kinose, Aasa Shimizu, Mamoru Kakuda, Satoshi Nakagawa, Tsuyoshi Takiuchi, Tadashi Iwamiya, Michiko Kodama, Eiji Kobayashi, Yutaka Ueda, Kenjiro Sawada, Tadashi Kimura
Published in Case Reports in Women's Health (2024-12-01)Get full text
Article -
4
Intramural pregnancy after intrauterine insemination in a nulligravid patient without previous uterine trauma, complicated by idiopathic thrombocytopenic purpura: A case report by Koyo Yamamoto, Tsuyoshi Takiuchi, Kengo Kiso, Saki Ishii, Satoshi Nakagawa, Yasuto Kinose, Michiko Kodama, Yutaka Ueda, Kenjiro Sawada, Takahiro Tsuboyama, Tadashi Kimura
Published in Case Reports in Women's Health (2025-03-01)Get full text
Article -
5
Safety and efficacy of Ninjin’yoeito along with iron supplementation therapy for preoperative anemia, fatigue, and anxiety in patients with gynecological disease: an open-label, si... by Taro Yagi, Kenjiro Sawada, Mayuko Miyamoto, Yasuto Kinose, Satoshi Nakagawa, Tsuyoshi Takiuchi, Michiko Kodama, Eiji Kobayashi, Kae Hashimoto, Seiji Mabuchi, Takuji Tomimatsu, Kiyoshi Yoshino, Tadashi Kimura
Published in BMC Women's Health (2022-06-01)Get full text
Article -
6
H2Bub1 loss is an early contributor to clear cell ovarian cancer progression by Adam J. Ferrari, Priyanka Rawat, Hannah S. Rendulich, Akshaya V. Annapragada, Yasuto Kinose, Xiaoming Zhang, Kyle Devins, Anna Budina, Robert B. Scharpf, Marilyn A. Mitchell, Janos L. Tanyi, Mark A. Morgan, Lauren E. Schwartz, T. Rinda Soong, Victor E. Velculescu, Ronny Drapkin
Published in JCI Insight (2023-06-01)Get full text
Article -
7
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models by Hyoung Kim, Haineng Xu, Erin George, Dorothy Hallberg, Sushil Kumar, Veena Jagannathan, Sergey Medvedev, Yasuto Kinose, Kyle Devins, Priyanka Verma, Kevin Ly, Yifan Wang, Roger A. Greenberg, Lauren Schwartz, Neil Johnson, Robert B. Scharpf, Gordon B. Mills, Rugang Zhang, Victor E. Velculescu, Eric J. Brown, Fiona Simpkins
Published in Nature Communications (2020-07-01)Get full text
Article -
8
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer by Haineng Xu, Sarah B. Gitto, Gwo-Yaw Ho, Sergey Medvedev, Kristy Shield-Artin, Hyoung Kim, Sally Beard, Yasuto Kinose, Xiaolei Wang, Holly E. Barker, Gayanie Ratnayake, Wei-Ting Hwang, Ryan J. Hansen, Bryan Strouse, Snezana Milutinovic, Christian Hassig, Matthew J. Wakefield, Cassandra J. Vandenberg, Clare L. Scott, Fiona Simpkins
Published in iScience (2024-07-01)Get full text
Article -
9
CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models by Haineng Xu, Erin George, Yasuto Kinose, Hyoung Kim, Jennifer B. Shah, Jasmine D. Peake, Benjamin Ferman, Sergey Medvedev, Thomas Murtha, Carter J. Barger, Kyle M. Devins, Kurt D’Andrea, Bradley Wubbenhorst, Lauren E. Schwartz, Wei-Ting Hwang, Gordon B. Mills, Katherine L. Nathanson, Adam R. Karpf, Ronny Drapkin, Eric J. Brown, Fiona Simpkins
Published in Cell Reports Medicine (2021-09-01)Get full text
Article
